RE: Food for thought21 Aug 2020 12:55
Thanks Anthony im fully aware of the Phases of clinical trials. I just don't sit easy when companies use deliberate language like "not futile". However in other reports and updates the overall language used seems encouraging and just wanted to discuss something that people may have missed.
Going back to MRx-4D0004 i really think this will through a curve ball into the SP. Everyone is getting excited about MRx0518 but here we have a phase II study on a Covid drug and very little chat about it. This brings SNG to mind for me when I was following it through is trial phases. The language used by the key people for Mrx-4D0004 is far more positive for me than with with MRx0518.
4D's Chief Scientific Officer, Alex Stevenson, commented:
If MRx-4DP0004 is successful in this study it would represent a highly significant breakthrough in the global fight against the novel coronavirus pandemic."
Dr. Dinesh Saralaya (Consultant Respiratory Physician and Associate Director of Research at Bradford Teaching Hospitals NHS Foundation Trust, and the National Institute for Health Research's (NIHR) Clinical Lead for Respiratory industry studies), commented:
"As well as its appropriate mechanism of action, the highly favourable safety profile of MRx-4DP0004 makes it a particularly attractive candidate for COVID-19 patients, and may potentially allow us to prevent or delay their progression to requiring ventilation and intensive care."